Net Loss per Share
|3 Months Ended|
Mar. 31, 2017
|Earnings Per Share [Abstract]|
|Earnings Per Share [Text Block]||
7. Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share for the three months ended March 31, 2017 were 11,489,515 and 57,341,642, respectively, and for the three months ended March 31, 2016 were 8,992,428 and 7,858,899, respectively.
The following tables set forth the computation of diluted net loss per weighted average number of shares outstanding attributable to Synthetic Biologics and Subsidiaries for the three months ended March 31, 2017 and 2016 (in thousands except share and per share amounts):
The entire disclosure for earnings per share.
Reference 1: http://www.xbrl.org/2003/role/presentationRef